Annovis Bio, Inc.

NYSE ANVS

Annovis Bio, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024

Annovis Bio, Inc. Operating Cash Flow is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating cash flow is cash generated from the company’s regular business operations.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NYSE: ANVS

Annovis Bio, Inc.

CEO	Dr. Maria L. Maccecchini Ph.D.
IPO Date	Jan. 29, 2020
Location	United States
Headquarters	1055 Westlakes Drive
Employees	6
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Artificial Intelligence (AI) Biotechnology Clinical Trials Personal Care Robotics Vaccines

Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Key trends

Past 5 years